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Summary
The pathophysiology of hyperparathyroidism (HPT) relates to
the loss of normal feedback control of parathyroid hormone
secretion by extracellular calcium. Why the parathyroid cell
loses its normal sensivity to calcium is unknown. Consistent
with the essential role of vitamin D in parathyroid cell regula-
tion, restriction fragment length polymorphisms (RFLPs) at
the vitamin D receptor (VDR) gene locus have been recently
postulated to be responsible for differential VDR transcription
and/or mRNA stability, contributing to the parathyroid tumori-
genesis. Particularly, common VDR allelic variants have been
related to differences in the incidence of both primary and
secondary HPT, and in serum PTH levels as well as in calcium
regulation of PTH release. However, agreement on these rela-
tionships is not universal among different populations. In this
study we investigated the role of VDR and calcium sensing re-
ceptor (CaSR) gene RFLPs in 100 uremic secondary HPT pa-
tients (mean age 58.2±6.7 yrs; mean dialytic age 7.1±2.0 yrs)
compared to 200 age and sex matched controls. Apa I, Bsm I,
and Taq I RFLPs at the 3'-end of VDR gene locus as well as
Fok I RFLP at the translation initiation codon of the VDR gene
were determined after PCR amplification and indicated re-
spectively as A-a, B-b, T-t, and F-f, uppercase letter signifying
the absence and lowercase letter the presence of the restric-
tion site. The 3 polymorphisms in exon 7 of the CaSR gene
(T/G at codon 986, A/G at codon 990, and G/C at codon 1011)
were evaluated by PCR amplification and direct sequencing.
Chi squared analysis revealed no significant difference in the
distribution of any of the VDR or CaSR genotypes in subjects
with secondary HPT compared to controls. Secondary HPT
patients were divided into two major groups according to
serum PTH levels: group 1 with higher PTH levels, requiring
parathyroidectomy, and group 2 with serum PTH levels below
120 pg/ml. Interestingly, a trend for a higher prevalence of
VDR genotype aabbTT in group 1, with respect to group 2 was
observed (P=0.07; Chi-squared test). Taken together, these re-
sults suggest that VDR and CaSR gene RFLPs are not directly
involved in parathyroid tumorigenesis and in determining the
incidence of secondary HPT. However, VDR gene RFLPs
might be useful in predicting the progression of secondary
HPT as well as the severity of the disease. 
KEY WORDS: uremic hyperparathyroidism, VDR gene polymorphism, calci -
um sensing receptor gene, parathyroid tumorigenesis.
Introduction
The pathophysiology of hyperparathyroidism (HPT) relates to the
loss of normal feedback control of parathyroid hormone secre-
tion by extracellular calcium. However, why the parathyroid cell
loses its normal sensivity to calcium is unknown. Parathyroid
adenomas are of monoclonal origin, but it does not exclude influ-
ence by both stimulatory and inhibitory factors regulating neo-
plastic growth. Additionally, the monoclonal phase could be pre-
ceded by a period of polyclonal hyperplasia, which is possibly af-
fected by several factors. The clonal origin of most parathyroid
adenomas suggests a defect at the level of the gene(s) control-
ling the regulation and/or expression of PTH or also the prolifera-
tion of parathyroid cells (1-5). Vitamin D exerts an important role
in parathyroid regulation and specific vitamin D receptors (VDR)
have been identified in parathyroid glands (6). It has been
demonstrated that calcitriol, via its receptor, constitutes an im-
portant regulator of parathyroid cell growth (7, 8) and directly in-
teracts with parathyroid hormone (PTH) secretion by inhibiting
PTH synthesis at the level of gene transcription (9, 10). De-
rangements in vitamin D receptor function and/or expression
have recently been suggested in the pathogenesis of both pri-
mary and secondary HPT (11-13). Particularly, in the nodules of
severe uremic parathyroid hyperplasia, an increased set-point
and decreased expression of both the calcium sensing receptor
(CaSR) and VDR have been observed. The VDR gene is locat-
ed in the long arm of chromosome 12 and possesses several
polymorphic sites (14). In the last years, several studies showed
a relationship between VDR allelic variants and calcium metabo-
lism, indicating the VDR gene as a major candidate gene for os-
teoporosis (15-16). Consistent with the essential role of vitamin
D in parathyroid cell regulation, restriction fragment length poly-
morphisms (RFLPs) at the vitamin D receptor (VDR) gene locus
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have been recently postulated to be responsible for differential
VDR transcription and/or mRNA stability, contributing to the
parathyroid tumorigenesis. Common VDR allelic variants have
been related to differences in the incidence of both primary and
secondary HPT, and in serum PTH levels as well as in calcium
regulation of PTH release (17-24). Moreover, association studies
investigating intron 8 (B / b and A / a alleles) and exon 9 (T/ t a l l e-
les) of V D R gene polymorphisms, detected by BsmI, ApaI and
TaqI endonucleases respectively, showed a higher prevalence
of b a T haplotype in Swedish patients affected by primary hyper-
parathyroidism (PHPT) (25, 26). These results were not con-
firmed in a Japanese population study (27), even if an associa-
tion study on a Spanish postmenopausal women population with
PHPT failed to demonstrate a role of BsmI VDR polymorphism
in the pathogenesis of parathyroid adenomas (28). However,
agreement on these relationships is not universal among differ-
ent populations and genetic differences among ethnical groups
could account for such discrepancies. In the present study we in-
vestigated the role of VDR and calcium CaSR gene RFLPs in
100 uremic secondary HPT patients compared to 200 age and
sex matched controls.
Materials and methods
Subjects
The study population comprised 100 patients affected with ure-
mic secondary HPT and 200 age and sex matched controls.
Patients had been recruited as part of a multicentric Italian
study, including the Nephrology and Dyalisis Units of Bari,
Cinisello Balsamo, Desio, Florence, Milan and Reggio Emilia.
The inclusion criteria for the study were the following: age> 65
years, dyalitic age >2 years, mean Al levels <40 mg/l, serum in-
tact PTH levels <120 pg/ml (Group 1) or >600 pg/ml (Group 2).
The cause of renal failure was chronic glomerulonephritis in
43, nephroangiosclerosis in 14, tubulo-interstitial nephritis in
10, polycystic kidney disease in 10, diabetic glomerulosclerosis
in 7, nephrotuberculosis in 1, and other causes in 15. 
Controls were selected from a cohort of 500 women and 200
men visited in Florence for osteoporotic risk evaluation which
had previously participated to genetic association studies on
VDR polymorphisms (16, 29). Clinical characteristics of pa-
tients and controls are given in Table I. 
Genetic analysis
Genomic DNA was isolated from EDTA blood samples by a
standard phenol-chloroform extraction procedure. Apa I and
Taq I RFLPs at the 3'-end of VDR gene locus as well as Fok I
RFLP at the translation initiation codon of the VDR gene were
determined after PCR amplification and indicated respectively
as A-a, T-t, and F-f uppercase letter signifying the absence and
lowercase letter the presence of the restriction site (Fig. 1). 
The 740 base pair fragment of the VDR gene, including the
Apa I and Taq I restriction sites in intron 8 and exon 9, was am-
plified according to Morrison et al. (15), by using the specific
primers 5'- C A G A G C A T G G A C A G G G A G C A A -3'
and 5'- G C A A C T C C T C A T G G C T G A G G T C T C -
3'. PCR products were then digested with Apa I and Taq I re-
striction endonucleases (Boheringer Mannheim, Milan, Italy),
respectively at 37° C and 65° C, for 4 hours.
The 265-bp fragment of genomic DNA containing the Fok I
polymorphic portion of exon 2 was amplified by PCR, as de-
scribed by Gross et al. (26), with the following primers: 5'-A G
C T G G C C C T G G C A C T G A C T C T G C T C T-3' and
5'-A T G G A A A C A C C T T G C T T C T T C T C C C T C-
3'. PCR products were digested with Fok I restriction endonu-
clease (New England Biolabs, Beverly, MA, USA) at 37° C for
4 h and then electrophoresed through a 3% low melting point
agarose gel, containing ethidium bromide. The presence of the
restriction site, that generates two fragments of 196 bp and 69
bp, was indicated with f, while its absence, resulting in a single
uncut 265 bp fragment, with F. 
Subjects were scored as aa, tt, ff homozygotes, Aa, Tt, Ff het-
erozygotes and AA, TT, FF homozygotes according to the di-
gestion pattern.
Exon 7 polymorphisms at the CaSR gene locus (Fig. 2) were
determined by direct dideoxy sequencing (ABI Prism 310,
Perkin Elmer, Monza, Italy) using fluorescently labelled primers
as previously described (30-32). 
Results
The frequency distribution of VDR and CaSR genotypes were
in Hardy-Weinberg equilibrium. The distribution of Apa I a n d
Taq I genotypes was very similar to what previously reported in
Caucasian populations of European ancestry, while significant-
ly differed from what observed in populations of Asiatic ances-
tr  (14). The distribution of CaSR genotypes did not vary from
that previously observed in Canadian population (31).
Chi squared analysis revealed no significant difference in the
L. Gennari et al.
Table I - General characteristics of uremic secondary HPT patients
and controls.
Characteristic Secondary HPT Controls
Number 100 200
Gender (male/female) 57/43 108/92
Age (yrs) 58.2±6.7 59.5±8.4
Hemodyalisis (age) 7.1±2.0 –
PTH (pg/ml) 548±102 42±5
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Figure 1 - Polymorphisms at the human VDR gene.
Figure 2 - Polymorphisms at the human CaSR gene.
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distribution of any of the VDR or CaSR genotypes in subjects
with secondary HPT compared to controls. When controls were
subgrouped in osteoporotics and non osteoporotics, according
to W.H.O. criteria (33), we observed a statistically significant in-
creased prevalence of “AA”, “tt” and “ff” VDR genotypes in os-
teoporotics than in non osteoporotics (Tab. II), and of “ff” VDR
genotype in secondary HPT patients than in osteoporotics
(Tab. III). Conversely, CaSR polymorphism distributions did not
vary among secondary HPT, osteoporotic and non osteoporotic
groups (Tab. IV). Secondary HPT patients were divided into
two major groups according to serum PTH levels: group 1 in-
cluding patients with higher PTH levels, unresponsive to med-
ical treatment and thus requiring parathyroidectomy, and group
2 including subjects with serum PTH levels below 120 pg/ml.
Interestingly, as shown in Table V, a trend for a two-fold in-
creased prevalence of VDR genotype “aaTT” in group 1, with
respect to group 2 was observed (P=0.07; Chi-squared test).
Discussion
Patients on long term hemodialysis caused by chronic renal
failure commonly have accompanying renal bone disease, one
of the major factors underlying this disease being secondary
hyperparathyroidism. Parathyroid hyperplasia and high levels
of immunoreactive PTH are present in the early stage of sec-
ondary hyperparathyroidism (34). Clonal analysis has shown
that in renal hyperparathyroidism the parathyroid glands initially
grow diffusely and polyclonally, with successive development
of foci of nodular hyperplasia and possibly of monoclonal neo-
plasia. Somatic changes of specific genes have been suspect-
ed of being responsible for parathyroid tumorigenesis in uremic
hyperparathyroidism. However, the genetic loci responsible for
tumor development remain to be identified and heterogeneous
genetic abnormalities may contribute to the progression of sec-
ondary parathyroid hyperplasia. The initial stimulus for PTH hy-
persecretion is thought to be predominantly a chronic reduction
of ionized calcium in the extracellular fluid, caused by the re-
duced production of 1,25 (OH)2 vitamin D and/or to phosphate
retention. Although secondary hyperparathyroidism is some-
times managed by calcium supplementation, by oral calcitriol
therapy and by restriction of phosphate intake, many patients
remain unresponsive to these conservative treatments (35).
Lack of response to treatment may be due to alterations in the
calcium sensing set-point and/or to an increased functional
parathyroid gland mass (36). To date, there are conflicting data
regarding the relative contribution of gland size and set-point
abnormalities to non-suppressible PTH in hemodialysis pa-
tients with secondary hyperparathyroidism (37-40). Many prior
studies provided evidence for a calcium sensing abnormality in
a subset of patients with severe hyperparathyroidism (37), but
recent studies have failed to identify calcium set point abnor-
malities in normocalcemic patients with secondary hyper-
parathyroidism of different severity (38). Similarly, in spite of
parathyroid gland enlargement, it has been difficult to conclu-
sively show that gland size is responsible for impaired calcium-
mediated PTH suppression in these patients. Whereas some
studies have found a relationship between basal circulating
PTH concentrations and parathyroid gland size (38), other in-
vestigations have not (40). Several studies have also suggest-
ed that resistance of parathyroid cells to 1,25 (OH)2 vitamin D
might underlie the secondary hyperparathyroidism in uremia
Genetic polymorphisms of vitamin D receptor and calcium sensing receptor gene in uremic secondary hyperparathyroidism
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Table II - Distribution of VDR 3’-end (Apa I and Taq I) genotypes in
uremic secondary HPT patients and controls (osteoporotics and
non osteoporotics).
Genotype SHPT Controls
OP Non OP
AAtt 14 24* 18
AATt 15 14* 10
AATT 12 16* 16
AaTt 33 38* 39
AaTT 16 11* 19
aaTT 20 17* 18
* P<0.05 OP vs non OP,Chi-squared test.
Table III - Distribution of VDR transcription initiation codon (Fok I)
genotypes in uremic secondary HPT patients and controls (osteo-
porotics and non osteoporotics).
Genotype SHPT Controls
OP Non OP
FF 58* 37 44
Ff 39* 44 47
FF 13* 19 19
* P<0.05 SHPT vs OP,Chi-squared test.
Table IV - Distribution of Exon 7 CaSR genotypes in uremic secon-
dary HPT patients and controls (osteoporotics and non osteoporo-
tics).
SHPT Controls
OP Non OP
Codon 986
G/G 75 63 65
T/G or T/T 25 37 35
Codon 990
A/A 93 90 88
A/G 17 10 12
G/G – – –
Codon 1011
C/C 88 91 93
C/G 12 19 17
G/G – – –
Table V - Distribution of VDR 3’-end (Apa I and Taq I) genotypes in
uremic secondary HPT patients.
Genotype PTH<120 pg/ml PTH>600 pg/ml
AAtt 18 (16.6%) 14 (10.3%)
AATt 15 (10.4%) 18 (29.5%)
AATT 12 (4.2%)1 –
AaTt 18 (37.5%) 11 (28.2%)
AaTT 19 (18.8%) 15 (12.8%)
aaTT 16 (12.5%) 11 (28.2%)
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(41) and reduction of VDR density is believed to participate in
the pathogenesis of this resistance. However, the results of
biochemical studies addressing VDR numbers in the parathy-
roids are still controversial, some finding a decreased VDR
content in the parathyroid glands of uremic patients (42) and
animals (43, 44), while others finding no such decrease (45,
46). Moreover, some other studies have recently shown a re-
duced nuclear uptake of calcitriol-VDR complex by uremic ul-
trafiltrate, suggesting an inhibited interaction of calcitriol recep-
tor with DNA during chronic renal failure (47, 48). Consistent
with the essential role of active vitamin D in parathyroid regula-
tion, a varied VDR expression due to allelic polymorphisms at
the VDR gene locus could be relevant in chronic renal failure
and may play a role in the increased proliferation of parathyroid
cells as well as in the progression of HPT in uremic patient, ac-
counting for the variation in the degree of secondary HPT ob-
served in this patient population. To this regard, Howard et al.
firstly associated the VDR “BB” genotype with a lower de-
crease in PTH levels after oral administration of calcitriol, sug-
gesting that different 1,25 dihydroxyvitamin D concentrations
are required to produce similar calciotropic responses in the
different Bsm I homozygotes of the VDR gene (24). Possibly,
the parathyroid gland in the low bone density “BB” group could
result less sensitive to the negative feedback of 1,25-(OH)2 vit-
amin D. On the contrary, in 1995 Carling et al. described an in-
creased prevalence of the VDR “b b” genotype but not of the
“BB” genotype in patients affected with primary HPT respect to
controls (17), suggesting that the presence of the “b” allele may
blunt the antiproliferative effect of vitamin D on parathyroid
cells and the inhibitory action of vitamin D on PTH transcrip-
tion, possibly by impaired VDR expression. However, the same
authors did not observe any difference in the distribution of the
“b b” VDR genotype in a subset of 34 uremic secondary HPT
subjects (19). Subsequent association studies on the relation-
ship between VDR polymorphisms and uremic secondary HPT
yielded conflicting results, some describing an increased
prevalence of “b b” genotype in secondary HPT, while others
reporting no significant differences in the distribution of geno-
types (18, 20-23). Data from the present study confirm the sig-
nificant segregation of VDR genotypes with osteoporotic risk in
Italian population, as previously observed in larger samples
(16, 29), but failed to detect a major role of these polymor-
phisms in the determination of secondary HPT, in uremia. In-
terestingly, a trend for a two-fold increased prevalence of
“a a T T” VDR genotype in group 1 (high PTH levels), with re-
spect to group 2 (low PTH levels) was observed, suggesting a
more severe degree of HPT in those patients with “aa” or “TT”
(and thus “b b”, being this allele in linkage disequilibrium with
“aa” and “TT” alleles) VDR allelic variants. The latter finding is
in keeping with those from previous studies showing increased
intact PTH levels in secondary HPT subjects with “a a”, b b” ,
and “TT” VDR genotypes (20-23). Moreover, a trend for a de-
creased prevalence of “f ” VDR allelic variant in secondary HPT
patients with respect to controls was observed. The possibility
of an association of secondary HPT with the Fok I polymor-
phism in the VDR gene deserves further investigation in larger
populations as well as in longitudinal studies.
Finally, in the same population of uremic secondary HPT pa-
tients we analyzed, for the first time, the role of polymorphisms
at an additional candidate gene in parathyroid diseases, the
human CaSR gene. The analyzed polimorphisms were located
in exon 7 of the CaSR gene, respectively in codon 986
(Ala/Ser), codon 990 (Arg/Gly), and codon 1011 (Gln/Glu).
They all encode non-conservative aminoacid changes in the
cytoplasmic tail of the CaSR, but their functional significance is
not known. Indeed, the codon 986 T/C polymorphism, has
been recently associated with variation in serum calcium levels
in a Canadian female population (31), giving rise to the possi-
b lity of a role of this polymorphism in disorders of calcium reg-
ulation such as hyperparathyroidism. However, in the present
preliminary study, we did not observe any significant correla-
tion between the codon 986 CaSR polymorphism and uremic
secondary HPT or osteoporosis. Similar negative results were
observed for what concern codon 990 and codon 1011 CaSR
polymorphisms. 
Taken all together, these results suggest that both VDR and
CaSR gene polymorphisms are not directly involved in parathy-
roid tumorigenesis and in determining the incidence of sec-
ondary HPT. Further studies are needed to evaluate the possi-
ble role of VDR gene allelic variant in predicting the progres-
sion of secondary HPT as well as the severity of the disease.
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